Ascletis Pharma received FDA IND clearance for ASC-35, a once-monthly subcutaneous GLP-1/GIP dual peptide agonist targeting obesity. The clearance advances the candidate toward clinical evaluation in the U.S. and expands Ascletis’ metabolic disease development pipeline. The program is notable for the intended dosing frequency, positioning ASC-35 as a potential alternative in a crowded obesity market where long-acting incretin-based therapies have become central to treatment standards. With IND clearance in place, investors and competitors will focus on trial initiation timing, safety tolerability for the dual agonist mechanism, and eventual efficacy readouts versus established regimens. Regulatory milestones like IND clearance are a key gating step for developers, enabling first human studies and formal protocol execution.